Terrie Curran, Phathom Pharmaceuticals CEO

FDA de­ci­sion, launch of gas­troin­testi­nal drug de­layed af­ter ni­trosamine found in com­mer­cial batch­es

Take­da spin­out Phath­om Phar­ma­ceu­ti­cals’ lead gas­troin­testi­nal drug has hit a snag with the FDA, the com­pa­ny an­nounced Tues­day, and won’t hit …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.